Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease
The FDA approved Sanofi and Regeneron Pharmaceuticals drug Dupixent as a treatment for the inflammatory skin disorder chronic spontaneous urticaria. The regulatory decision comes two years after the agency turned down an application for the biologic drug in this indication.
